Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06933095 · ClinicalTrials.gov registry record · NA
Optimizing CNS DHA Delivery in Elderly Adults at Risk for Dementia
A NA study of Cognitive Decline and Memory Decline, sponsored by University of Cincinnati.
- Recruiting
- Registry status
- NA
- Development phase
- 153
- Enrollment target
- 1
- Study location
NCT06933095 is a NA study of Cognitive Decline and Memory Decline that is actively recruiting participants, run by University of Cincinnati. The registered enrollment target is 153 participants, below the 1,147-participant average among 61 other Cognitive Decline trials with a reported enrollment target (87% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06933095, a NA study of Cognitive Decline and Memory Decline, is actively recruiting participants, sponsored by University of Cincinnati.
- RECRUITING
- Registry status
- NA
- Development phase
- 153 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this placebo-controlled trial is to compare the effects of 24-weeks supplementation with LPC-DHA and TAG-DHA on cerebrospinal fluid and blood DHA levels, as well as biomarkers of central neurodegenerative and neurotrophic activity, in elderly adults experiencing early signs of cognitive/memory decline including those with mild cognitive impairment (MCI). Extant evidence supports our overarching hypothesis that LPC-DHA supplementation will be more effective than TAG-DHA for increasing central (CSF) DHA levels and improving biomarker profiles in elderly adults. To assess this hypothesis, the following aims are proposed: SPECIFIC AIM 1: To compare the effects of LPC-DHA and TAG-DHA supplementation on peripheral and CSF DHA levels in elderly adults experiencing early signs of cognitive/memory decline. SPECIFIC AIM 2: To compare the effects of LPC-DHA and TAG-DHA supplementation on neurotrophic and neurodegenerative biomarkers. Secondary Aim: To investigate whether changes in CSF DHA levels correlate with changes in objective measures of executive functioning and episodic memory performance.
Conditions Studied
Interventions
- DIETARY_SUPPLEMENT LPC-EPA+DHA capsules containing omega-3 fatty acids EPA and DHA esterified to lysophosphatidylcholine (LPC-EPA+DHA)(Trade name: Lysoveta)
Study Locations (1)
Ohio
- University of Cincinnati, Department of Psychiatry and Behavioral Neuroscience - Cincinnati
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 153 participants |
| Start Date | 2024-09-15 |
| Est. Completion | 2029-09-15 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06933095
The ClinicalTrials.gov registry entry for NCT06933095 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 153 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,147-participant average among 61 other Cognitive Decline trials with a reported enrollment target (87% lower). The listed sponsor is University of Cincinnati, which has 245 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Cognitive Decline appearing as the primary indexed condition, and to 1 intervention - of which LPC-EPA+DHA capsules containing omega-3 fatty acids EPA and DHA esterified to lysophosphatidylcholine (LPC-EPA+DHA)(Trade name: Lysoveta) is the first listed.
NCT06933095 reports 1 study location spanning 1 distinct geographic area - top geographies include Ohio.
Frequently Asked Questions
What is clinical trial NCT06933095 about?
NCT06933095 is a clinical study titled "Optimizing CNS DHA Delivery in Elderly Adults at Risk for Dementia". The purpose of this placebo-controlled trial is to compare the effects of 24-weeks supplementation with LPC-DHA and TAG-DHA on cerebrospinal fluid and blood DHA levels, as well as biomarkers of central neurodegenerative and neurotrophic activity, in elderly adults experiencing early signs of cogniti...
What is the current status of trial NCT06933095?
This trial is currently recruiting. It is a NA study. The enrollment target is 153 participants. The study started on 2024-09-15. Estimated completion is 2029-09-15.
What conditions does trial NCT06933095 study?
This clinical trial studies the following conditions: Cognitive Decline, Memory Decline, Eldery People, DHA CNS Delivery.
What interventions are being tested in trial NCT06933095?
The interventions under investigation include: LPC-EPA+DHA capsules containing omega-3 fatty acids EPA and DHA esterified to lysophosphatidylcholine (LPC-EPA+DHA)(Trade name: Lysoveta) (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT06933095?
This trial is sponsored by University of Cincinnati, which has 245 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06933095 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cognitive Decline
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
δ in Dementia Clinical Trials
RECRUITING · NA
-
mPATH for Low-income Older Adults
RECRUITING · NA
-
MindWalk Intervention for Older South Asian Caregivers of People With Cognitive Disabilities (CD)
RECRUITING · NA
-
Preventing Cognitive Decline by Reducing BP Target Trial
RECRUITING · NA
-
Essential Fats For Enhancing Cognitive Thinking (EFFECT) Study
RECRUITING · NA
-
Exercise Adherence and Cognitive Decline: Phase 2
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.